Tumour necrosis factor alpha inhibitors, such as infliximab, and other biologic agents are associated with increased risk of opportunistic infection, including tuberculosis. Tuberculosis infections associated with infliximab tend to present atypically and can be difficult to diagnose, as they are more likely to manifest as extrapulmonary or disseminated disease. The authors report a case involving a 29-year-old male patient who died following 16 days of treatment for undifferentiated sepsis and who was found on autopsy to have widespread disseminated tuberculosis. Prior to the onset of illness, the patient had received infliximab for the treatment of Crohn’s disease. Following discussion of the case, the authors review the definition of adverse events, provide a root cause analysis of the cognitive errors and breakdowns in the health care system that contributed to the reported outcome, and identify opportunities to address these breakdowns and improve patient safety measures for future cases.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1qhHWTC
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Many different quantitative techniques have been developed to either assess Environmental Justice (EJ) issues or estimate exposure and dose ...
-
Leddsmerter kan ha mange årsaker. Traumatiske, immunologiske og infeksiøse lidelser må vurderes. En god anamnese kan sette oss på rett spor...
-
Outcomes of Drug-Induced Sleep Endoscopy-Directed Surgery for Pediatric Obstructive Sleep Apnea. Otolaryngol Head Neck Surg. 2017 Nov ...
-
Evidence-Based Medicine: Cleft Palate. Plast Reconstr Surg. 2017 Jan;139(1):191e-203e Authors: Woo AS Abstract LEARNING OBJECTIVES:...
-
Trends in Otolaryngology Consultation Patterns at an Academic Quaternary Care Center. JAMA Otolaryngol Head Neck Surg. 2017 Jan 05;: ...
-
Apple, Facebook, Google and Microsoft claim the president’s ban on people from seven Muslim-majority countries inflicts "substantial ha...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου